Trial
NCT02195817
Study of 18 mg Selincro® As-needed Use, in the Treatment of Patients With Alcohol Dependence in Primary Care
Phase IVTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
H. Lundbeck A/S
Collaborators
—
Condition
Alcohol Dependence
Intervention
Selincro® 18 mg with continuous psychosocial support: Cohort A
Why stopped
The study was terminated due to enrolment challenges
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-02-28